E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
relapsed or refractory CLL/SLL |
|
E.1.1.1 | Medical condition in easily understood language |
relapsed or refractory CLL/SLL |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060671 |
E.1.2 | Term | B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia Criteria (IWCLL, Hallek 2008) with incorporation of the clarification for treatment related lymphocytosis (Hallek 2012) (hereafter referred to as IWCLL 2008 criteria) in patients with relapsed or refractory CLL/SLL |
|
E.2.2 | Secondary objectives of the trial |
To compare efficacy between the two treatment groups in terms of: • To evaluate overall survival (OS) • To evaluate IRC-assessed overall response rate (ORR) per IWCLL 2008 criteria • To evaluate patient-reported outcome (PRO) by FACiT-Fatigue • To evaluate hematological improvement Safety • To evaluate the safety and tolerability of ibrutinib compared to of Ofatumumab
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients will be considered for inclusion in this study if they meet all of the following criteria: 1. Men and women ≥ 18 years of age 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. • Diagnosis of CLL or SLL that meets IWCLL 2008 criteria. • Active disease meeting at least 1 of the IWCLL 2008 criteria for requiring treatment. • Must have received at least one prior therapy for CLL/SLL. • Must not be appropriate for treatment or retreatment with purine analog based therapy. • Measurable nodal disease by CT. • Must have the following laboratory parameters met for inclusion: • Absolute neutrophil count (ANC) ≥ 750 cells/μL (0.75 x 109/L), independent of growth factor support. • Platelet count ≥ 30,000 cells/μL (30 x 109/L) without transfusion support. • Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) < 2.5 x upper limit of normal (ULN). • Total bilirubin ≤ 1.5 x ULN. • Estimated creatinine clearance (ie, estimated Glomerular Filtration Rate, eGFR) using Cockcroft-Gault ≥ 30 mL/min. • Patient must be able to receive outpatient treatment and laboratory monitoring at the institution that administers study drug for the entire study. |
|
E.4 | Principal exclusion criteria |
Patients will be ineligible for this study if they meet any of the following criteria: 1. Known central nervous system (CNS) lymphoma or leukemia 2. Known prolymphocytic leukemia or history of or currently suspected Richter’s transformation 3. Missing or incomplete documentation of cytogenetic and/or FISH results reflecting the presence or absence of 17p del and the percentage of cells with the deletion in patient records prior to randomization 4. Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP) defined as declining hemoglobin or platelet count secondary to autoimmune destruction within the screening period or requirement for high doses of steroids (>20mg daily of prednisone daily or equivalent). 5. Prior exposure to ofatumumab or to ibrutinib (PCI-32765) or randomization into an ibrutinib study 6. Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days prior to first dose of study drug 7. Corticosteroid use > 20 mg within 1 week prior to first dose of study drug, except as indicated for other medical conditions such as inhaled steroid for asthma, topical steroid use, or as premedication for administration of study drug or contrast. Patients requiring steroids at daily doses > 20 mg prednisone equivalent systemic exposure daily, or those who are administered steroids for leukemia control or white blood cell count lowering are excluded 8. Radio- or toxin-conjugated antibody therapy within 10 weeks prior to first dose of study drug 9. Prior autologous transplant within 6 months prior to first dose of study drug 10. Prior allogeneic stem cell transplant within 6 months prior to randomization or with any evidence of active graft versus host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug. 11. Major surgery within 4 weeks prior to first dose of study drug 12. History of prior malignancy, with the exception of the following: a) Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to Screening and felt to be at low risk for recurrence by treating physician b) Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled non-melanomatous skin cancer c) Adequately treated cervical carcinoma in situ without current evidence of disease 13. Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or history of myocardial infarction within 6 months prior to first dose with study drug 14. Unable to swallow capsules or disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption such as; malabsorption syndrome, resection of the small bowel, or poorly controlled inflammatory bowel disease affecting the small intestine 15. Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment) or ongoing intravenous anti-infective treatment 16. Known history of infection with human immunodeficiency virus (HIV) 17. Serologic status reflecting active hepatitis B or C infection. Patients with hepatitis B core antibody positive who are surface antigen negative or who are hepatitis C antibody positive will need to have a negative polymerase chain reaction (PCR) result prior to enrollment. Those who are hepatitis B surface antigen positive or hepatitis B PCR positive and those who are hepatitis C PCR positive will be excluded. 18. History of stroke or intracranial hemorrhage within 6 months prior to randomization. 19. Pregnant or lactating women 20. Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator’s opinion, could compromise the patient’s safety or put the study at risk 21. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 28 days of first dose of study drug 22. Requires treatment with a strong CYP3A4/5 inhibitor |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the study is PFS, as assessed by IRC review per IWCLL 2008 criteria |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Depends on PFS events as the primary endpoint of this study is PFS, as assessed by IRC review per IWCLL 2008 criteria. |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints are : Efficacy •OS •ORR defined as the proportion of patients who achieve a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) per IWCLL 2008 criteria over the course of the study as evaluated by an IRC • PRO as measured by FACiT-Fatigue. • EFS, for which progressive disease, death, and non-response at 3 months are defined as events. Non-response is defined as patients who do not achieve CR, CRi, nPR, PR, or PR with lymphocytosis. • Hematological improvement in the subset of patients with cytopenia(s) at baseline assessed by time to and percentage of patients with improvement in blood counts.
Safety • To compare the safety and tolerability between the two treatment groups
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Depends on PFS events as the primary endpoint of this study is PFS, as assessed by IRC review per IWCLL 2008 criteria. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 47 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
France |
Ireland |
Italy |
Poland |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |